Back to News
Market Impact: 0.38
Adagene Gains NMPA Clearance On Phase 1 For ADG138 In Solid Tumors, Set To Begin In Q4 '26
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Adagene received NMPA clearance in China for its investigational new drug application for ADG138 to treat solid tumors. The authorization enables clinical development of the oncology candidate in China and is a positive pipeline milestone for the clinical-stage biotech.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
ADAG0.72
More News
- How the US midterm elections reflected resistance to data centres
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- OpenAI to press ahead with data-center expansion despite midterm sweep, CFO tells CNBC
- SoftBank, ABB consider China carve-out to rescue $5.4bn robotics deal
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Bitcoin rebounds to $76,000, but $1.3 billion ETF exodus tests recovery